Top Gainers Biotech- Zalicus Inc (NASDAQ:ZLCS), VIVUS, Inc. (NASDAQ:VVUS), Seattle Genetics, Inc. (NASDAQ:SGEN)
Zalicus Inc. (ZLCS), as well as Epirus Biopharmaceuticals, Inc. (Epirus), released that they have entered into a definitive contract under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. The president and CEO of Epirus, Amit Munshi stated that under the new firm structure, they will persist to aggressively advance our pipeline of biosimilars, and address diverse worldwide biosimilar markets through local partnerships.
Zalicus Inc (NASDAQ:ZLCS) [Trend Analysis] gained 31.07%, closing the day at $1.35 in last regular trading while in after hours trading shares moved down -1.48%. The firm has market capitalization of $35.22M, and enterprise value of $20.99M. It has price over sales value of $1.82 for the most recent quarter. Corporation has the total of cash of $17.96M as compares to total debt of $8.77M for the most recent quarter with the current ratio of 1.39% for the most recent quarter.
Why Investors Show Confidence on (NASDAQ:ZLCS)
VIVUS, Inc. (VVUS) reported that J. Martin Carroll, Mark B. Logan as well as Robert N. Wilson have determined not to stand for re-election when their terms run out at the Annual Meeting of Stockholders, to be held on June 20, 2014. The chairman of VIVUS, Michael J. Astrue stated that they are grateful to Marty, Mark and Bob for their tireless efforts on behalf of VIVUS.
Shares of VIVUS, Inc. (NASDAQ:VVUS) [Trend Analysis] increased 4.58% to the trading at $5.25. The firm has 52-week low range of $4.71 and 52-week high price was $15.62. The recommendation trends from street professionals are, stock rated at “buy” by 2 analysts, while 2 analysts rates as a “sell” security.
Moving Forces Behind (VVUS) On Confident Run! Click Here
Seattle Genetics, Inc. (SGEN) released that it will post its first quarter 2014 financial results on Thursday, May 1, 2014, following the close of financial markets. Following the declaration, firm management will host a conference call and webcast discussion of the results and provide a general corporate update.
Seattle Genetics, Inc. (NASDAQ:SGEN) [Trend Analysis] surged 4.19%, closing the day at $38.57, after wavering among $36.80 and $39.20 during the trading session. Its net profit margin in lasted declared quarter was -23.25% as compared to -23.22% in previous year in same year. Its beta value stands at 1.17 times. The stock has a 52-week high price of $55.99 and its 52-week low price was $28.15.
Why (SGEN) Rallied in Active Trading, Find here
Read Full Disclaimer Here